ÌìÃÀ´«Ã½

Houston, TX USA

Our News on Newswise
View All >

Newswise: 680d2a9f7319c_AACR2025NewsReleaseAbstractsWEB05Srour-Tuesday.jpg

AACR: New CAR T Cell Therapy Benefits Patients with Advanced Thyroid Cancers

• Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors • One patient experienced a complete response, and one...
28-Apr-2025 5:05 AM EDT Add to Favorites

Newswise: 680d322cdf4b6_AACR2025NewsReleaseAbstractsWEB04Heymach-Monday.jpg

AACR: HER2 targeted therapy shows promise in previously treated lung cancers

• Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer
28-Apr-2025 5:10 AM EDT Add to Favorites

Newswise: 680d32e2f3d29_AACR2025NewsReleaseAbstractsWEB02YapSunday-1.jpg

AACR: First-in-Class Covalent Werner Helicase Inhibitor Shows Clinical Proof-of-Concept in Phase I Trial

• RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors • Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors • This class of drugs is important because many...
26-Apr-2025 2:30 PM EDT Add to Favorites

Newswise: 680d325328707_AACR2025NewsReleaseAbstractsWEB03PatelSunday-2.jpg

AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer

· LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself · Over two-thirds of patients had successful treatment with the higher dose of LUT014...
26-Apr-2025 2:55 PM EDT Add to Favorites

Newswise: 680d325e2be69_AACR2025NewsReleaseAbstractsWEB01YapSunday.jpg

AACR: Olaparib and Pembrolizumab Combination Shows Early Promise in Molecularly Selected, Tumor-Agnostic Trial

• Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations • Combination demonstrated complete responses and partial responses in different cancer...
26-Apr-2025 2:55 PM EDT Add to Favorites

AACR: Researchers share promising results from MD Anderson clinical trials

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025. Findings include a...
25-Apr-2025 1:00 PM EDT Add to Favorites

AACR: Five MD Anderson researchers honored with 2025 Scientific Achievement Awards

Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards and honors at the American Association for Cancer Research (AACR) Annual Meeting 2025.
21-Apr-2025 7:25 PM EDT Add to Favorites

Newswise: 6801aef65ce96_JohnWeinsteinheadshot.jpg

AACR: MD Anderson’s John Weinstein elected Fellow of the AACR Academy

John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology at The University of Texas MD Anderson Cancer Center, has been elected to the 2025 class of Fellows of the American Association for...
18-Apr-2025 10:00 AM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

Newswise: basen-engquistphoto.JPG
AUDIO

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

Newswise: 196697_Schembre_S.JPG
AUDIO

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

See All Experts

Our YouTube Videos
View All >

About

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals†rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Experts

Twitter

Facebook

close
1.37065